Duchem Bio Sees 47% Rise in Operating Profit... Net Profit Declines
"Expanding Sales of Alzheimer's Treatments"
Duchem Bio, a company specializing in radiopharmaceuticals, announced on the 29th that it recorded sales of 38.5 billion won and operating profit of 7.4 billion won in 2025. Last year’s sales increased by 8% compared to the previous year, while operating profit rose by 47%. Net profit for the period was 6.3 billion won, a decrease from 8 billion won in the previous year.
The company stated that the increase in diagnostic product sales following the introduction of an Alzheimer's treatment was a key factor behind these results. It explained that, starting from December 2024, sales of diagnostic products 'Vizamil' and 'Neuracheck', which are linked to prescriptions for Alzheimer's treatments, contributed to the rise in both sales and operating profit.
Hot Picks Today
!["Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"](https://cwcontent.asiae.co.kr/asiaresize/93/2026051507261063923_1778797570.png)
"Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"
- "Now Our Salaries Are 10 Million Won a Month" Record High... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- While All Eyes Were on Samsung and Hynix, This Company Surged 50% to New Highs in Four Days [Weekend Money]
- Train and Bus Collide in Bangkok, Thailand: At Least 8 Dead, Over 30 Injured
- Experts Already Watching Closely..."Target Price Set at 970,000 Won" Only Upward Momentum Remains [Weekend Money]
Kim Sangwoo, CEO of Duchem Bio, said, "Based on our diagnostic product business, we plan to expand into the field of therapeutic radiopharmaceuticals in the future."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
